177 results on '"Pandya, Shree"'
Search Results
2. A Cross-Sectional Study of School Experiences of Boys with Duchenne and Becker Muscular Dystrophy
3. Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis
4. Cardiovascular health supervision for Duchenne Muscular Dystrophy; data from the MD STARnet
5. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
6. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy
7. Consensus-based care recommendations for adults with myotonic dystrophy type 1
8. Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy
9. Health services received by individuals with duchenne/becker muscular dystrophy
10. Myotonic dystrophy health index: Correlations with clinical tests and patient function
11. SPINAL MUSCULAR ATROPHY FUNCTIONAL COMPOSITE SCORE: A FUNCTIONAL MEASURE IN SPINAL MUSCULAR ATROPHY
12. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
13. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
14. SIBLING CONCORDANCE FOR CLINICAL FEATURES OF DUCHENNE AND BECKER MUSCULAR DYSTROPHIES
15. RASCH ANALYSIS OF CLINICAL OUTCOME MEASURES IN SPINAL MUSCULAR ATROPHY
16. Role Attainment in Emerging Adulthood: Subjective Evaluation by Male Adolescents and Adults with Duchenne and Becker Muscular Dystrophy.
17. Splicing biomarkers of disease severity in myotonic dystrophy
18. Corticosteroids in Duchenne muscular dystrophy: Major variations in practice
19. A quantitative measure of handgrip myotonia in non-dystrophic myotonia
20. Differentiation of Pediatric-Onset Duchenne and Becker Muscular Dystrophy Subphenotypes Using Data from the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet).
21. Role of disease severity, illness perceptions, and mood on quality of life in muscle disease
22. PALLIATIVE CARE SERVICES IN FAMILIES OF MALES WITH DUCHENNE MUSCULAR DYSTROPHY
23. Open-Label Trial of Recombinant Human Insulin-like Growth Factor 1/Recombinant Human Insulin-like Growth Factor Binding Protein 3 in Myotonic Dystrophy Type 1
24. Oral Corticosteroids and Onset of Cardiomyopathy in Duchenne Muscular Dystrophy
25. Delayed Diagnosis in Duchenne Muscular Dystrophy: Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)/STI>
26. COMPUTERIZED HAND GRIP MYOMETRY RELIABLY MEASURES MYOTONIA AND MUSCLE STRENGTH IN MYOTONIC DYSTROPHY (DM1)
27. SEVERITY, TYPE, AND DISTRIBUTION OF MYOTONIC DISCHARGES ARE DIFFERENT IN TYPE 1 AND TYPE 2 MYOTONIC DYSTROPHY
28. Limb-Girdle Muscular Dystrophy in the United States
29. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy
30. Validation of the individualised neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in USA versus UK
31. Association of genetic mutations and loss of ambulation in childhood‐onset dystrophinopathy.
32. Left ventricular dysfunction in Duchenne muscular dystrophy.
33. A Review of MD STARnet's Research Contributions to Pediatric-Onset Dystrophinopathy in the United States; 2002-2017.
34. The effect of steroid treatment on weight in nonambulatory males with Duchenne muscular dystrophy.
35. Health Care Transition Experiences of Males with Childhood-onset Duchenne and Becker Muscular Dystrophy: Findings from the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet) Health Care Transitions and Other Life Experiences Survey.
36. Health profile of a cohort of adults with Duchenne muscular dystrophy.
37. A Pilot Survey Study of Adherence to Care Considerations for Duchenne Muscular Dystrophy.
38. Rasch analysis of the Pediatric Evaluation of Disability Inventory-computer adaptive test (PEDI-CAT) item bank for children and young adults with spinal muscular atrophy.
39. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
40. Respiratory Care Received by Individuals With Duchenne Muscular Dystrophy From 2000 to 2011.
41. Rehabilitative technology use among individuals with Duchenne/Becker muscular dystrophy.
42. Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet.
43. Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the...
44. Noninvasive Respiratory Care Received by Individuals With Duchenne Muscular Dystrophy Since 1979.
45. Use of Complementary and Alternative Medicine by Males With Duchenne or Becker Muscular Dystrophy.
46. Poster 452 Risk Factors for Fractures Among Males with Duchenne or Becker Muscular Dystrophy
47. Use of Corticosteroids in a Population-Based Cohort of Boys With Duchenne and Becker Muscular Dystrophy.
48. Change in Natural History of Duchenne Muscular Dystrophy With Long-term Corticosteroid Treatment: Implications for Management.
49. Clinical Outcome Measures in Spinal Muscular Atrophy.
50. Mutation Analysis in a Population-Based Cohort of Boys With Duchenne or Becker Muscular Dystrophy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.